We are proud to announce that PhenoPath is now a Quest Diagnostics Company.
Idiopathic hypereosinophilic syndrome (HES), or primary eosinophilia, is a chronic and typically slowly progressive disease that eventually results in organ damage. Several molecular mechanisms have been identified, including FIP1L1-PDGFRα and rearrangements of PDGFRβ and FGFR1. The presence of any of these abnormalities is associated with positive response to imatinib mesylate (Gleevec) therapy. While molecularly defined eosinophilias are relatively rare, up to one-quarter of HES patients have been shown to harbor one of these mutations. In these patients, imatinib therapy improves 5-year survival rates to from ~75% to 90-95% and reduces rates of progression from 50% down to less than 1%.
Organ: Blood/Bone Marrow
CPT Code(s): 88374 x3
Turnaround Time: Within 4-6 business days of receipt
Schedule: Monday - Friday
• Peripheral blood, Preferred: 3 ml in sodium heparin (green top) / Acceptable: 3 ml in EDTA (purple top) - OR - • Bone marrow aspirate, Preferred: 1-2 ml in sodium heparin (green top) / Acceptable: 1-2 ml in EDTA (purple top) - OR - • Fresh tissue in RPMI